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1. Introduction 
Sepsis is a devastating condition characterized by the systemic activation of inflammatory 
and coagulation pathways in response to microbial infection of normally sterile parts of the 
body. Severe sepsis, defined as sepsis with at least one dysfunctional organ, is the leading 
cause of death in non-coronary intensive care units and is associated with mortality rates of 
30-50%. The development of experimental sepsis models to elucidate the progression and 
pathophysiology of clinical sepsis spans the past eight decades. Studies utilizing models of 
intra-abdominal sepsis began in the 1930’s with the isolation of endotoxin and the 
intravenous or peritoneal infusion of live organisms, a model which dominated sepsis 
research for over 30 years. In the 1960’s, a transition was made from endotoxemia models to 
a focus on bacteremia. Such models include the injection of live bacteria (Pseudomonas 
aeruginosa, Escherichia coli, and Staphylococcus aureus), inoculation of feces, and 
intramuscular, intraperitoneal and subdermal implantation of feces-containing capsules and 
sponges. Following the use of endotoxemia and bacteremia models, various models 
involving ischemia and bowel perforation were developed. These models led to the 
development of the most frequently used sepsis model today, cecal ligation puncture (CLP) 
and more recently, the colon ascendens stent peritonitis (CASP) model. Over the years 
several large animal models of sepsis have also been developed, of which canine, ovine, 
bovine, rabbit, and non-human primates have proven to be most useful. However, the 
translation of findings and inferences from animal sepsis models to human sepsis remains a 
challenge. In this chapter, we will provide an overview of experimental models of sepsis, 
with focus on the merits and limitations of each model. We will also focus on strategies that 
may improve the translation of results from animal studies to human sepsis. This requires 
consideration of the limitations of current sepsis models including supportive therapies, 
considering age, gender, obesity, and exposure to pathogens in animals used, and 
addressing the risk of bias in experimental sepsis models. 
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2. History of experimental sepsis models 
Sepsis is a serious, complicated, heterogeneous condition involving a dysregulated host 
response to an initial infection and subsequent hemodynamic, cardiovascular, respiratory, 
metabolic, hormonal, inflammatory, innate and adaptive immune changes (1;2). 
Experimental sepsis models have been utilized extensively and developed over the last eight 
decades to study the progression and pathophysiology of clinical sepsis (3-5). Intra-
abdominal sepsis models were introduced in the 1930s with the isolation of endotoxins and 
the intravenous or peritoneal infusion of live organisms, models which dominated sepsis 
research for thirty years. Upon the discovery of new antimicrobial compounds, treatment of 
intra-abdominal abscesses became a clinical focus in the 1960s and a transition was made 
from the endotoxin model to the bacterial model of infection (4). These models used fecal 
pellets and the addition of an adjuvant to induce infection with the goal of studying 
peritonitis rather than isolated abscess formation (3). However, these models fell short as 
mortality rates relied heavily on bacterial counts and bacterial composition which varied 
widely between both species and individual subjects. Additionally, the bacterial overload at 
non-physiologically relevant levels and lack of a sterile environment contributed to a much 
greater mortality rate in experimental sepsis compared to what was observed clinically (4).  
To overcome these limitations, the introduction of defined bacterial inoculum models in the 
1970s improved sepsis modeling immensely. These models were also used in landmark 
studies which uncovered the two-stage nature of intra-abdominal sepsis with gram-negative 
enteric bacteria inducing the peritonitis phase and anaerobic bacteria responsible for 
subsequent abscess formation (3). Antibiotic agents tested using defined bacterial models 
were successful in either improving survival or reducing abscess formation but were not 
successful in improving both criteria. This led to the development of models which more 
closely resembled the progression clinical sepsis.  
In the ‘60s and ‘70s, the Clowes group and Wright group were able to create septic 
conditions in dogs by ligating the cecum at the ileocecal valve, successfully demonstrating 
both the initial hyperdynamic phase and later hypodynamic phase of sepsis, but neither 
groups documented bacterial cultures to validate dissemination of pathogens in the 
peritoneum or circulation (6-9). A small animal model was later introduced by Ryan et al 
whereby the rat cecum is ligated distal to the ileocecal valve, devascularizing the cecum and 
introducing a necrotic component to experimental sepsis (10). It is this latter model which 
lead to the most frequently used animal model of sepsis, cecal ligation and puncture. 
3. Common models of polymicrobial sepsis 
3.1. Cecal Ligation and Puncture (CLP) 
The CLP model of intra-abdominal sepsis was introduced by Wichterman, Baue, and 
Chaudry in 1980. The group published an insightful review of previous models and 
introduced a novel sepsis model still widely regarded as the gold standard for modelling 
polymicrobial sepsis today—the cecal ligation and puncture (CLP) model. Rats were fasted, 
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their cecum was ligated distal to the ileocecal valve, the antimesenteric cecal surface was 
punctured twice with an 18G ½ needle, and received subcutaneous saline post-operatively. 
This model induced polymicrobial infection (blood cultures positive for Escherichia coli, 
Streptococcus bovis, Proteus mirabilis, Enterococcus, and Bacteroides fragilis) and bacteremia 
(peritoneal cavity fluid positive for the above microbes as well as Streptococcus viridians and 
Clostridium sporogenes) and a 70% mortality rate. Mildly ill rats sacrificed 10 hours following 
CLP demonstrated the early hyperdynamic phase of sepsis (increased blood flow to organs, 
hyperinsulinemia, and hyperglycemia) while rats sacrificed 16-24 hours post-operative 
represented a hypodynamic late septic state (decreased blood flow to organs, 
hypoinsulinemia, hypoglycemia, and high serum lactate levels) (3). The results of this model 
correlate with clinical sepsis conditions as patients who are initially normotensive, show an 
increase in cardiac output, have low peripheral resistance, and increased total oxygen 
consumption, conditions which reverse in late septic shock (3). 
Multiple aspects of the CLP procedure address the complex, of the clinical course of sepsis. 
CLP induces polymicrobial infection of the peritoneum with a localized infectious focus, 
release of bacteria and endotoxic molecular components of pathogens (pathogen-associated 
molecular patterns or PAMPs) into normally sterile areas in the host, and subsequent 
translocation of enteric bacteria into the bloodstream, modelling the stages of intra-
abdominal clinical sepsis (3). Under anaesthesia, the cecum is exposed and trauma is 
induced via a midline skin laparotomy and blunt dissection of the peritoneum to exteriorize 
the cecum. Avoiding damage to the mesenteric vessels, the cecum is ligated with suture 
distal to the ileocecal valve, punctured once or twice (through-and-though) from the 
mesenteric to anti-mesenteric direction halfway between the ligation and cecal end, and 
aspirated for trapped gasses (3). A small amount of fecal content is extruded to allow for 
patency of the puncture(s) and continuous flow of feces post-operatively. The cecum is 
returned into the peritoneal cavity taking care not to spread fecal content on the incision and 
the peritoneum and abdomen are closed separately with sutures (11).  
3.1.1. Host response to CLP 
Significant elements of the host response to CLP-induced polymicrobial sepsis are present in 
clinical sepsis. The hemodynamic profiles, cardiovascular response, metabolic phases, 
systemic  involvement of cytokine responses (ex. profiles of interleukins), changes in the 
innate and adaptive immune response, and abnormalities in mediators of coagulation which 
occur following CLP are also observed in the clinical course of sepsis (12). Moreover, CLP 
involves multiple, complicated elements which are unaccounted for by models of 
endotoxemia and bacterial inoculum. These include a laparotomy which mimics surgery-
induced trauma in the septic patient, the presence of inflamed tissue (peritonitis), necrosis 
via ligation of the cecal end, apoptosis of specific leukocytes, bacteremia induced by 
pathogens from a host-derived flora (fecal spillage), and translocation of enteric, living, 
multiplying bacteria into the bloodstream (12). The inclusion of these elements as part of the 
CLP model improves the clinical relevance of outcomes from these preclinical studies. 
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As observed in clinical sepsis, the hyperinflammatory state which occurs during the 
systemic inflammatory response syndrome (SIRS) transitions to an immunosuppressed state 
characterized by a compensatory acute response (CARS) (12;13). However, the point at 
which this transition occurs in both clinical and experimental sepsis is unclear. The early 
hyperdynamic stage of sepsis and the later hypodynamic state following the CLP procedure 
is indicated by changes in response to immune challenge and changes in peripheral blood 
cells, plasma levels of cytokines, and chemokines. Neutropenia and lymphopenia are 
characterized by significant peripheral blood alterations rapidly following CLP parallel to 
leukocytosis or leukocytopenia observed in the clinical SIRS condition (1;12-14). Following 
CLP, total white blood cells, polymorphonuclear cells, and lymphocytes increase rapidly 
within the first 2 hours, decrease from 2-4 hours, and plateau until endpoint at 8 hours 
following CLP (15). The pro-inflammatory response is also characterized by significant 
increases in cytokines TNFα and IL-6 and chemokines KC, MIP-2, and MCP-1 from non-
detectable plasma levels that increase and remain elevated over an 8 hour period (12;15). 
Several studies have demonstrated the importance of an early pro-inflammatory response in 
the progression of sepsis. Antibody-mediated blockade of IL-6 (16;17), complement factor 
C5a or C5a receptor (18-20), and depletion of neutrophils offered protective effects and 
increased survival of animals subjected to CLP. 
While anti-inflammatory proteins like IL-10 and glucocorticoids are crucial for dampening 
and terminating the inflammatory response (21-23), the hypoinflammatory phase of 
experimental sepsis characterized by neutrophil paralysis (shutting down of signaling 
pathways), apoptosis of lymphocytes and dendritic cells, and elevations in anti-
inflammatory mediators significantly increase the susceptibility of the septic host to 
nosocomial infection. It is during this hypoinflammatory, immunosuppressed state when 
most mortality is observed in clinical sepsis (21) however it is unknown if this holds true in 
animal sepsis. 
3.1.2. Modifying severity in CLP 
Multiple elements of the CLP procedure can be modified to model the wide spectrum of 
conditions observed in clinical sepsis. These factors include the number of cecal punctures, 
gauge of needle used to puncture the cecum, and the length of cecum ligated in the animal 
(3). However, there are conflicting findings as to whether the number of cecal punctures 
affects disease severity. One group reported that two cecal punctures does not result in a 
significant increase in mortality but is associated with a decrease time to endpoint (24). 
Variations in the CLP protocol can be used to produce different disease severities and mimic 
various stages of the sepsis spectrum from the rapid onset of a robust, hyperinflammatory 
state to a gradual progression of severe sepsis to an immunosuppression in septic shock. For 
instance, modifications such as using a smaller gauge/thicker needle (18G ½ rather than a 
26G½) or ligating a larger amount of cecum (by placing the suture proximal to the ileocecal 
valve) can increase the severity and produce a mortality rate that may be more clinically 
relevant (25).  
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The flexibility in modeling various severities of disease, ability to recreate hemodynamic, 
metabolic, and immune changes, the inclusion of surgical trauma, necrosis, and apoptosis of 
specific cell types which more closely correlate with clinical sepsis contribute to the 
acceptance of CLP as the gold standard for modeling polymicrobial, intra-abdominal sepsis. 
3.2. Colon Ascendens Stent Peritonitis (CASP) 
Almost two decades following the introduction of the CLP model by Chaudry et al., Zantl et 
al. introduced a polymicrobial, peritonitis sepsis model termed colon ascendens stent 
peritonitis or CASP (26). The CASP model is a reproducible model suitable for studying the 
pathophysiology of abdominal sepsis and can be successfully varied by using stents of 
different diameters ranging from 14G to 22G (26;27). It can also be used to study surgical 
interventions which involve the elimination of the infectious focus by stent removal (27). 
The prevalence of the CASP model in sepsis studies has only recently increased. Currently, 
the number of studies utilizing the CLP sepsis model far exceed those using CASP (25).  
In the CASP procedure, a laparotomy is performed to exteriorize the cecum, terminal ileum, 
and ascending colon. The ascending colon wall is pierced and the suture is fixed on the 
colon wall 15 mm distal from the ileocecal valve. A prepared stent or cannula is used to 
puncture the ascending colon around 1-2 mm proximal from the suture and the cannula is 
inserted into the colon and sutured securely. Fecal content is milked through the stent which 
provides a pathway between the intestinal lumen and the peritoneum, allowing 
unobstructed influx of enteric bacteria into the peritoneal cavity (26;28). Disease severity of 
this model, can be modified by adjusting the size of the cannula used for stenting from 14 G 
to 20 G (100% lethality and less than 50% mortality at 48 hours following surgery, 
respectively) (24;28). Within 3 hours of stent implantation, levels of circulating and systemic 
cytokines and chemokines including TNFα, IFN-γ, IL-1, IL-12, IL-18, KC/GRO-α, MCP-1, 
and anti-inflammatory IL-10 increase (26;29;30). Unlike CLP however, progression of sepsis 
in the CASP model appears less dependent on the initial immune response elicited by TNFα 
and more heavily focused on innate immune activation via toll-like receptors (TLRs) and 
TLR signalling. In several studies, progression of sepsis required the TLR adaptor molecule 
MyD88 and antibody mediated inhibition of TLR4/MD2 prevented lethality induced by 
CASP (31;32). IL-12 and inducible nitric oxide synthase (iNOS) offer some antibacterial and 
immunoprotective effects since mice genetically deficient of IL-12 and iNOS are more 
susceptible to CASP-induced sepsis (33). Additionally, exogenous addition of complement 
factor C3 (34) and activated protein C (35) offered cytoprotective and anti-inflammatory 
effects against CASP-induced lethality. 
The CASP model of polymicrobial sepsis and peritonitis appears to have substantial utility, 
however our understanding of signalling pathways and the pathobiology which results in 
disease in this model are lacking. Animals subjected to CASP appear to mount a rapid, 
stronger immune response than animals subjected to CLP but further experimentation is 
required to determine the efficacy of using CASP as a sepsis model. Undoubtedly, the use of 
CASP will increase in prevalence as the pathophysiology and underlying mechanisms of 
disease which produce the septic conditions are uncovered. 
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3.3. CLP vs. CASP 
Notable differences in the host response to CLP versus CASP-induced sepsis have been 
documented. The progression of sepsis in the CLP model involves TNFα-mediated 
activation of the immune response while the CASP model is less dependent on the initial 
immune response elicited by TNFα and more so dependent on TLR activation and 
signalling (12;25;29). One study comparing the two distinct models found that bacterial 
counts of peritoneal lavage, liver, lung, and serum levels of TNFα, IL-1β, and IL-10 increase 
steadily over a 24 hour period in the CASP model and were significantly higher than that of 
mice subjected to CLP (24). In this study, the authors observed continuously low bacterial 
counts and cytokine levels at all time-points as well as abscess formation around the cecum 
in mice subjected CLP. In light of these observations, it has been suggested that CASP is a 
true model of peritonitis with early SIRS, while CLP more closely mimics abscess formation 
(24;25). Alternatively, others interpret the rapid elevations in systemic cytokines, bacterial 
counts and strong immune response following CASP to be comparable to that observed in 
endotoxemia models and the inflammatory reactions characterized by protracted cytokine 
profiles following CLP to more closely reflect clinical sepsis (12).  
Discrepancies between the host response to CLP versus CASP have been observed in studies 
using genetically-modified animals, although consensus on the interpretation of these 
results is lacking. While TNFα-deficient mice were protected in a CLP model, 
TNFRp55/TNFR1-deficient mice did not appear to have an altered resistance to CASP-
induced sepsis (26;36). However, the differences observed may be due to the incomplete 
abolishment of TNFα activity as these mice may be deficient in only one of two TNF 
receptors, abolishing the cytotoxic TNFR1 and leaving the protective TNFR2 intact (37). 
Additionally, IFNγ exhibited protective effects in a CASP model and not in CLP-induced 
sepsis (26;36). Abolishing cytokine IL12p40 rendered the host more susceptible to CASP-
induced sepsis while the same deficiency was found to either have no significant effect in 
some CLP studies (36) or increase susceptibility to sepsis in others CLP studies (38). The 
discrepancies in experimental outcomes of studies using CLP and CASP may be results of 
differences in the host response between these sepsis models, and an incomplete 
understanding of the pathophysiology of each model. Careful consideration should be taken 
to choose an appropriate model to address the primary research question to be investigated. 
3.4. Limitations of current models 
Earlier models of endotoxemia and bacterial inoculum fall short in modelling the complex 
changes which occur in clinical sepsis. Many cardiovascular, respiratory, metabolic, 
hormonal, inflammatory, innate and adaptive immune changes associated with the 
spectrum of septic conditions cannot be sufficiently reproduced by a single injection of 
endotoxin or bacteria (12). Injection of isolated microorganisms fails to mimic the host 
response to the diversity of causative agents in clinical sepsis. A specific instance is the 
injection of an endotoxin like lipopolysaccharide (LPS, a component of the cell wall of gram-
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negative bacteria) (4). LPS endotoxemia is dependent on TLR4 signalling and represents one 
specific aspect of the immune response, not the complex interactions of multiple signalling 
pathways during the progression of sepsis. Endotoxin injection and bacterial inoculum are 
followed by rapid elevations in cytokines which are much higher than what is observed in 
human sepsis (4). These models are more reflective of endotoxic shock rather than sepsis 
due to the overload of endotoxins in murine animals which exhibit a much higher endotoxin 
resistance than humans, further decreasing the clinical relevance of these studies (12). 
Moreover, these increases are transient, occurring in a short time span, and fail to reflect the 
complex physiological response in clinical sepsis. 
Although surgical polymicrobial sepsis models show a greater clinical relevance than earlier 
models of endotoxemia and bacterial or fecal injections, both CLP and CASP are not without 
limitations. While the severity of experimental sepsis can be controlled by modifying certain 
elements of a CLP protocol (e.g. length of ligated cecum) these factors may also decrease the 
consistency between animals and reproducibility of the study, as the amount of cecum 
ligated may vary between subjects (3). More contributing factors to inter-animal variability 
include differences in the amount of fecal content in the cecum at the time of surgery, the 
size of cecum of each animal, and bacterial flora in different animals. Moreover, conflicting 
findings over the effect of the number of punctures on disease severity further highlight 
differences that may result due to surgical manipulation at the hands of different 
experiments (24). Another limitation of CLP and CASP…….. 
Another limitation of CLP and CASP is the inter-study variations due to differences in 
protocols used between investigators. The number of cecal punctures and sizes of needles 
used to perforate the bowels vary between studies using the CLP model. Likewise, 
differences in the diameter of catheter used, location of stent insertion and suturing in the 
CASP model also influence disease severity (24;25). While some of these limitations will 
inevitably affect the consistency and reproducibility of sepsis studies in animals, standard 
protocols can be enforced to reduce potential discrepancies. 
4. Sepsis in large animal models 
Small size, shorter reproductive cycles as well as less housing and maintenance costs are 
some advantages of utilizing small animals for scientific research. However certain 
physiological features of small animals vary considerably from its human counterparts (39). 
In addition, serial tissue and blood samples cannot be extracted from small animals, 
increasing the number of animals required to study whether an affect exists. Large animals, 
on the other hand not only allow serial sampling but also have very similar immunological 
and physiological functions to humans, rendering them better subjects to model clinical 
sepsis and drug testing. The Food and Drug Association (FDA) also recognizes the value of 
large animals requiring all new drug applications to include data from at least one non-
rodent animal. In this section the rabbit, canine, porcine, ovine and non human primate 
models of sepsis and their limitations will be discussed. 
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4.1. Rabbit models of sepsis 
A rabbit model of pneumococcal sepsis was developed in 1970. It encompasses several 
aspects of clinical sepsis including increased cardiac output and body temperature (40;41). 
This model involves the use of Diplococcus pneumoniae to induce sepsis and an inoculum of 1 
ml of medium containing rabbit blood and tryptase soy broth with 108 to109 colony forming 
units is administered intraperitoneally (40) Several other rabbit models of sepsis were 
developed to study lung injury. Matute Bello et al. observed that a dose of 109 cfu/clot 
induced a more persistent infection compared to 108 cfu/clot, while inoculation of 1010 
cfu/clot had lethal effects in a rabbit model of peritonitis (42). In this model, 
polymorphonuclear leukocyte (PMNs) function in the peritoneal cavity was perturbed 
suggesting potential contribution in the development of septic shock (42). Overall, the rabbit 
model of sepsis has been used to investigate physiological and immunological responses 
during sepsis and septic shock (43). 
4.2. Canine models of sepsis 
The canine models of endotoxemia and bacteremia have been used extensively to study 
cardiovascular function during sepsis. Dogs subjected to septic shock, show responses that 
parallel human sepsis. For example, there is a severe but reversible decrease in systolic 
ventricular function (44), a 32-108% increase in cardiac output, decrease in mean arterial 
pressure, and leukocytosis as well as increase in plasma epinephrine and norepinephrine 
levels during septic shock (45). Cytokine profiles in the canine model of endotoxemia also 
mirror those reported in human sepsis patients with a 62 fold increase in IL-6 mRNA in 
peripheral blood mononuclear cells (PBMC) and 4.5 fold increase in TNFα within the first 
hours compared to controls (46).  
Despite the analogous physiological responses, there are several limitations of this model 
pertaining to clinical relevance. Canines have an adrenergic sensitive sphincter around the 
hepatic vein which constricts during sepsis increasing intestinal venous pressure and 
damaging the mucosal barrier, increasing its relevance to a gut injury model (47;48). 
Another important limitation is the resistance of canines to endotoxins and the requirement 
of high LPS dosage to induce sepsis (39;49). This requirement for increased endotoxemia 
results in a severe hypodynamic response in canines (50) which does not mimic 
hyperdynamic human sepsis.  
4.3. Porcine models of sepsis 
Pigs are popular animals for since they are readily available and relatively easy to handle. 
Continuous infusion of live bacteria, endotoxins as well as CLP are some of the methods 
used to induce sepsis in pigs. Porcine models of sepsis have been used extensively to 
investigate therapeutic agents focusing on improving renal, hepatic, intestinal and 
cardiovascular function (51-53). For instance, using a porcine model of LPS induced shock, 
Cohen et al. observed that increasing levels of
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and glomerular filtration rate (51). In addition, the porcine model of fecal peritonitis has 
been previously used to investigate the impact of adding low dose arginine vasopressin 
(AVP) to norepinephrine infusion for improving organ function (52). In the AVP treatment 
group, renal function was significantly improved, and significantly less hepatic apoptosis 
compared to the group treated with norepinephrine alone, suggesting that the addition of 
AVP to norepinephrine improves renal function (52). 
The porcine model of fecal peritonitis has also been used to study acute lung injury associated 
with sepsis. Septic pigs have decreased left ventricular function, respiratory dysfunction as 
well as hemorrhage, pulmonary congestion associated with neutrophil infiltration 
characteristic of acute lung injury (53). This model has been further used to study effects of 
certain therapeutic agents such as N-acetylamrinone and L-arginine (54;55). 
Due to the close similarity between pig and human anatomies, these animals have also been 
utilized to develop techniques commonly performed on sepsis patients such as laparoscopy 
(56). Porcine models of neonatal sepsis also closely mimic the clinical course of neonatal 
sepsis with a significant decrease in systemic blood pressure (71 ± 3 mmHg in sepsis and 64 
± 3 mmHg in control at 3 h) and increases in serum levels of endotoxins, TNFα, and IL-6 
(57). Anatomical and physiological similarities between porcine and human anatomy have 
allowed for the successful testing of techniques and study of therapeutic agents which 
translate to human sepsis.  
4.4. Ovine models of sepsis 
In sheep, infusion of endotoxins (58), live bacteria as well as administration of fecal content 
into the abdominal cavity are some methods used to induce sepsis. The ovine model of 
sepsis has distinct similarities to human sepsis and several advantages over other animal 
models specifically regarding cardiopulmonary responses. One similarity between sheep 
and human sepsis is the biphasic cardiovascular profile. In endotoxemia models of ovine 
sepsis, two phases of cardiopulmonary function are observed (59). Within the first hour, the 
animal is in a hypodynamic state with a low cardiac index, myocardial contractility, high 
mean pulmonary arterial pressure, and pulmonary vascular resistance (59). The first phase 
is followed by a hyperdynamic state with significant increase in cardiac output (59). 
The ovine is also a popular specie to study sepsis associated with lung injury. Daniel Traber 
is a pioneer in developing the ovine model of 'smoke injury' which involves insufflating 
sheep with smoke from burning cotton cloth (60) and the 'ovine burn model' which involves 
third degree burns and smoke injury (61). Smoke inhalation is induced using a modified bee 
smoker filled with 40 g of burning cotton cloth attached to a tracheostomy tube through a 
modified endotracheal tube (61). Based on similar principles, the ovine model of 'smoke 
inhalation and septic shock' was developed to study sepsis associated with pneumonia that 
develops due to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) 
after smoke inhalation (62). In this model, the aforementioned technique of 'smoke 
inhalation’ is used to induce lung injury (63), followed by instilling bacteria such as 
Pseudomonas aeruginosa into the lungs (63;64).  
 Sepsis – An Ongoing and Significant Challenge 44 
Using the ‘ovine smoke inhalation and septic shock' model several therapeutic agents have 
been investigated for sepsis management. Necrosis and apoptosis in this model were 
improved by administration of WW-85, a peroxynitrite decomposition catalyst. Other 
notable changes include improved gas exchange, decreased levels of myeloperoxidase 
(MPO) and lung 3-nitrotyrosine (65). There was also an overall improvement in pulmonary 
function suggesting that blocking nitric oxide-peroxynitrite pathway may ameliorate some 
effects of septic shock (65).The ovine model of sepsis and septic shock has made important 
contributions in the areas of cardiovascular (66) and pulmonary research as well as in 
determining the efficacy of fluids (58) and therapeutic agents (67), such as anticoagulants 
(68) and recombinant human protein C (69) to improve sepsis outcomes. 
4.5. Non-human primate models of sepsis 
Due to genetic similarities to humans, non-human primates are an ideal model for testing 
species-specific therapies (70). The method of inducing sepsis and septic shock in baboons 
utilizes an intravenous infusion of live E.coli (70). Using the baboon model of sepsis, several 
therapeutic discoveries have been made, the most prominent one being Activated Protein C 
(APC) (71;72). Taylor et al. reported that co-administration of APC with E. coli at lethal 
doses reduces coagulopathic and hepatotoxic effects induced by E. coli. This blocking of 
lethal effects of E.coli disappeared when protein C activation was blocked in vivo (73). More 
recently Xu et al. also reported that histone levels increase following E.coli administration in 
baboons. Extracellular histones released in response to inflammatory stimuli and during 
sepsis contributes to endothelial dysfunction, organ failure and death (71). Xu et al. 
discovered that baboons co-administered with both APC and E.coli, were rescued from 
mortality (71). The success of APC in baboon model of sepsis, allowed for its use in the 
clinical setting, until its recent withdrawal from the market following a further phase III 
trial. Despite the advantages associated with baboon models of sepsis, risk of infectious 
disease transmission, high housing and maintenance costs, as well as the ethical concerns 
deter many investigators from utilizing these animals for sepsis research (49).  
4.6. Limitations of large animal models of sepsis 
Large animal models have provided tremendous insight into the pathophysiology of sepsis, 
however there are certain limitations to the use of these animals. Due to their large size, they 
are also more difficult to handle, house, and anaesthetize and in the case of primates, pose 
risks of cross transmissible diseases (47). 
5. Co-morbidities and sepsis 
There have been several therapeutic agents with positive outcomes in animal models 
however majority failed to show efficacy in clinical settings. This disconnect is partially due 
to discrepancies in translating findings from animal models to clinical sepsis. Defined 
human target populations and established severities of sepsis would allow for more realistic 
and applicable animal modelling. 
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Clinical studies report that individuals with co-morbidities such as diabetes are at a higher 
risk of mortality and morbidity from infectious diseases (74-77). It has also been estimated 
that greater than 50% of septic patients have at least one additional co-morbid condition 
(78). Therefore, incorporating co-morbid conditions into animal models is one method by 
which modeling clinical sepsis in animal models could be improved. 
5.1. Sepsis and diabetes 
Several animal studies and clinical trials have demonstrated that diabetes increases the risk of 
infections and mortality (74-77). A retrospective cohort study from Ontario, Canada by Shah et 
al. reported that almost half of the diabetic patients in their study (n=513,749) had a minimum 
of one case of infectious disease for which they were either hospitalized or received a 
physician claim (74). It was also found that bacterial infections and infections in general were 
also more commonly found in diabetics (74). From animal models of type II diabetes it is 
known that sepsis induced inflammation is more severe in diabetic animals (79). Septic 
diabetic animals also have increased bacteria load (80;81), altered levels of cytokine expression 
(81;82) and dysfunctional immune cells such as PMNs contributing to poor outcomes.  
Studies in animal models of obesity parallel the findings in diabetic animals. Strandberg et 
al. reported that mice fed a high fat diet (HFD) with saturated fats, had higher mortality 
rates when challenged with Staphylococcus aureus compared to mice fed a low fat diet (LFD) 
(83). The HFD fed group had increased bacterial load, decreased immune cell-mediated 
clearance of bacteria, and significantly elevated pro and anti-inflammatory cytokine levels 
compared to mice on a LFD (83). Therefore obesity can influence the response of immune 
cells to infections such as sepsis and thus have direct impact on sepsis outcomes.  
5.2. Urinary tract infection and sepsis 
The urogenital tract is the focus of infection in approximately 25% of all sepsis cases (84). 
Urinary tract infection (UTI) associated sepsis is predominantly found in elderly 
individuals, diabetics and immuno-suppressed patients (85). Several animal models have 
been developed to study different aspects of these co-morbid conditions. Harberg et al. 
developed a model of E.coli induced UTI by infecting urinary bladders of female mice by 
administrating bacteria via a urethral catheter (86). Pyelonephritis isolates (HU734) and 
normal fecal (414) E. coli were used to induce infection, where the pyelonephritis strains 
were discovered to remain in the system longer (86). UTI associated sepsis animal models 
have also been used to test potential therapeutic strategies. Reid et al. investigated whether 
competitive exclusion of uropathogenic bacteria would occur when animals were treated 
with indigenous bacteria (87). In female rats with chronic UTI induced by periurethral 
injections of agar beads with bacteria, rats exposed to indigenous bacteria , Lactobacillus casei, 
21 days before the uropathogen challenge, had no pathogenic bacteria or immune responses 
in the bladder and kidney for up to 60 days (87). Given the prevalence of UTi-associated 
sepsis in the clinical setting, using animal models which involve co-morbidities and 
common clinical infections will increase the relevance of these animal studies.  
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5.3. Genetics and sepsis 
Several studies have identified the implications of genetic variance, for immune responses to 
sepsis. Even while comparing across different strains of septic mice, mortality rates, liver 
MPO activity, metallothione mRNA, leptin as well as IL-10 levels are significantly higher in 
C57BL/6J compared to A/J mice (88). Thus, genetic differences in mice and possibly humans 
are associated with differences in the inflammatory processes initiated in response to 
infection that ultimately affects sepsis outcomes (88).  
Transgenic animal models have also been utilized extensively in sepsis research (89). 
Transgenic apolipoprotein (ApoE) polymorphs, ApoE3TR and ApoE4TR, generated by 
replacing mouse ApoE allele with its human counterpart coding sequences were used to 
investigate if ApoE genotype affects sepsis outcomes (89). ApoE is a ligand for low density 
lipoprotein (LDL) receptor, responsible for clearance of VLDLs and chylomicrons residues. 
ApoE plays key role in lipid metabolism (90) and mediates removal of inflammatory 
apoptotic substances (91). Mice with the human APOE4 allele have greater inflammatory 
response (with two to four fold increase in synthesis of cytokine) as well increased time to 
mortality (89). 
ApoE knockout mice (apoE -/-) generated by gene targeting are more susceptible to 
endotoxemia and K. pneumoniae compared to LDLr-/- mice implicating the role of apoE in 
modulating LPS induced inflammatory responses (92). Haraguchi et al. have reported using 
the ApoE-/- strain that administration of pioglitazone suppresses inflammation and improves 
survival in these mice, providing support for the use of peroxisome proliferator-activated 
receptor gamma (PPAR-γ) agonist as potential treatment option for severe sepsis (93). 
Other strains of transgenic mice have also been utilized for sepsis research such as mice with 
inactivated beta2 integrin CD11b. These transgenic mice are partially protected against 
micro-vessel permeability and edema formation, suggesting key role of Cd11b in lung PMN 
sequestration and vascular injury during the early phase of gram-negative sepsis (94). 
Lectin-like oxidized low density lipoprotein receptor 1 knockout (LOX-1-/-) mice have been 
used to investigate the role of LOX-1 in sepsis induced mortality. Wu et al. reported that 
LOX-1-/- mice with CLP-induced sepsis had decreased systemic inflammation, neutrophil 
migration to sites of infection, levels of pro-inflammatory cytokines, and lung edema as well 
as increased bacterial clearance implicating the key role of LOX-1 in systemic inflammation 
(95). Important findings have also been discovered in toll like receptor knockout mice (TLR-
/-) . Toll like receptors (TLRs) recognize different components of bacteria cell wall and 
mediate immune responses to infection. TLR-4 for instance interacts with LPS, activating the 
expression of target genes. TLR-/- knockout mice have been utilized to study dendrititc cell 
maturation and cytokine production (96), infections of the urogenital organs (97) and 
defense against infections such as murine tuberculosis (98) among several others aspects of 
adaptive and immune responses. 
Transgenic mice such as ob/ob have also been used to examine the effects of leptin 
deficiency on sepsis outcomes (99). Leptin deficiency, in ob/ob mice, is associated with 
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greater organ dysfunction and increased mortality rates during sepsis (99). Leptin signaling 
appears to improve survival and may be required for immune responses, implicating 
therapeutic potential for leptin analogues for sepsis. Thus transgenic mice have made 
important contributions to Improve our understanding of sepsis at physiological, 
immunological and cellular levels. 
6. Emerging preclinical research in sepsis: Neutrophil Extracellular Trap 
(NET) formation 
An emerging area of sepsis research involves the formation of neutrophil extracellular traps. 
In 2004, Brinkmann et al. characterized a novel mechanism of innate immunity exhibited by 
neutrophils. Upon stimulation by endotoxins or pro-inflammatory mediators, activated 
neutrophils released chromatin material composed of a DNA backbone and antimicrobial 
granular proteins in the form of neutrophil extracellular traps (NETs) (100). NETs ensnare 
circulating microorganisms, preventing further dissemination of pathogens in the 
vasculature while providing a scaffold for neutrophil granular proteins. This creates a high, 
local concentration of proteins with antimicrobial properties (100) and allows for 
microbicidal synergy, concentrating their ability to disarm and kill microorganisms (101). 
6.1. NETosis 
The formation of NETs, recently coined NETosis (100;102) is an active process. Cleavage of 
histones by neutrophil elastase is sufficient to cause decondensation of nuclear material 
(103) which can be observed before disintegration of nuclear and granule membranes. 
Chromatin material mixes with nuclear and granular proteins with potent antimicrobial 
properties and is released extracellularly (102;104) forming stretches of DNA and globular 
proteins with diameters of 15-17 nm and 25 nm respectively which can aggregate to form 
thicker threads around 50 nm in diameter (100). The process of NETosis is distinct from that 
of necrosis (the plasma membrane remains intact while nuclear and cytoplasmic granular 
components mix) and that of apoptosis (no phosphatidylserine exposure signaling 
phagocytosis, or nucleosomal cleavage) (102;105). 
NETosis can be experimentally induced by exposure to endotoxins (e.g. LPS), gram-negative 
and gram-positive bacteria, fungi, pro-inflammatory mediators (e.g. IL-8, phorbol myristate 
acetate or PMA a protein kinase activator), and activated platelets (103;106-111). NET 
formation in experimental conditions results in the release of proteins which degrade 
virulence factors expressed on the pathogen surface and create a toxic environment for 
invading microorganisms (102;107;112-115). NET-associated azurophilic granule proteins 
which have antimicrobial or immunomodulating effects include histones with specific post-
translational modifications (and histone cleavage products like buforin), cathepsin G, 
elastase, MPO, pentraxin, gelatinase (matrix metalloproteinase-9), catalase, lactoferrin, 
peptidoglycan recognition proteins (PGRPs), and bactericidal permeability-increasing 
protein (BPI) (100;107;116). NETs have also been shown to kill infectious organisms and 
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impair pathogenic invasion of gram-negative bacteria (e.g. Shigella flexneri), gram-positive 
bacteria (e.g. Staphylococcus aureus, Group A streptococcus), fungi (e.g. Candida albicans), and 
even viruses (e.g. influenza A virus) (100;102;106;107;107-110;112;114-117). 
6.2. NETosis in infection and sepsis 
In 2007, a landmark paper published by the Kubes group characterized the mechanism by 
which platelet-neutrophil interactions contribute to pathogenesis of severe sepsis. It was 
observed that LPS-induced endotoxemia in mice as well as plasma from severe sepsis 
patients were able to trigger NET formation but at a cost to the host. Upon detection of TLR4 
ligands (e.g. LPS), platelets bind to neutrophils adhered to the endothelium (118). Within 
minutes, TLR4-dependent platelet-neutrophil interactions resulted in the robust release of 
granules and DNA in the form of NETs the integrity of which was maintained under flow 
conditions reflective of physiologic shear forces in the microvasculature (0.5 dyne/cm2). 
NET-mediated bacterial clearance through trapping and ensnaring of bacteria was primarily 
observed in liver sinusoids and lung capillaries, areas with the greatest capacity for 
immobilizing bacteria due to the decreased lumen size of vessels (118). However, formation 
of NETs is not without a cost as it was also found to cause cellular and tissue damage to the 
host. In vitro, NET formation resulted in endothelial cell damage marked by increased 
staining of propidium iodide, a nucleic acid stain impermeable to viable cells (118). In vivo, 
NET formation was also found to cause hepatotoxicity in LPS-challenged mice indicated by 
the decreased perfusion of liver sinusoids and increase in levels of alanine aminotransferase, 
associated with platelet-mediated neutrophil activation. Given these findings, the authors 
propose that platelets act as a sensor or barometer (partially via TLR4 receptors) for 
pathogens in the blood, inducing a last resort immune response mediated by neutrophils to 
ensnare and kill bacteria at the expense of the host's tissues (118). In the already immune-
deregulated state of the septic host, NETs can exacerbate sepsis by releasing high 
concentrations of potent proteases, inducing further endothelial damage, and forming a 
chromatin meshwork, trapping host cells (erythrocytes, leukocytes, and platelets) which can 
potentiate inflammation, coagulation, ischemia, and hypoxia in downstream tissues. 
6.3. NET pathogenicity 
NETs induce pathogenic effects via multiple mechanisms. Platelet-mediated NET formation 
trapped platelets, leukocytes, and red blood cells causing microvascular plugging and areas 
of ischemia in downstream tissues (118;119). Ischemic conditions increase the production of 
IL-8 (120) and reactive oxygen species (121) both of which can induce further NET formation 
(122). Several lines of evidence also suggest that NETs exert pro-coagulant effects in sepsis 
and other conditions of deregulated coagulation and inflammation. In studies of thrombosis, 
NETs were found to interact closely with fibrin and platelets via von Willebrand factor, 
fibronectin, and fibrinogen, effectively stabilizing platelet-rich clots (119;123). NETs 
perfused with blood or platelet-rich plasma stimulated platelet aggregation and promoted 
thrombus formation (124). Another in vivo study observed that both DNA and RNA provide 
a surface template on which activation of the contact pathway via XIIa/XIa promoting fibrin-
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rich thrombus formation and decreased plasma clotting times (125). Antimicrobial 
proteins associated with NETs also exert pro-coagulant effects which are pathogenic to the 
host. Positively-charged histones promote red blood cell accumulation and platelet 
aggregation by electrostatic interactions with the negatively-charged cells (126). NET-
associated histones also impair the natural anticoagulant protein C, activate platelets, and 
induce thrombin generation via platelet TLR2 and TLR4-mediated mechanisms (124;127-
129). Additionally, histones induce prothrombinase activity, increased P-selectin expression, 
phosphatidylserine exposure, and FV activation (127).  
NETs and NET-associated proteins have also been found to exert pro-inflammatory effects. 
MPO released during NET formation binds the negatively-charged, proteoglycan-rich 
endothelium, inducing endothelial cell damage and vascular permeability (130;131). 
Incubation of NETs with human platelets and THP-1 cells resulted in the release of pro-
inflammatory cytokines including IL-1β, IL-8, and TNFα (132).  
The pathogenic nature of NETs is also supported by studies showing improved outcome 
associated with NET destruction via DNase administration (133). Furthermore, DNaseI-
deficient mice develop lupus-like symptoms induced by NET formation, indicating that 
NET removal is likely a crucial process in the proper immune response (123). The formation 
of NETs and release of NET-associated proteins (e.g. histones) potentiate the pro-
inflammatory and pro-coagulant response, both of which contribute to end organ 
morphology in sepsis. These changes include neutrophil adherence to microvascular 
endothelium, inflammatory infiltration, vacuolization of epithelial and endothelial cells, 
fibrin deposition, microvascular ruptures with intra-alveolar hemorrhaging, and the 
formation of platelet-rich micro- and macrovascular thrombi (118;127;129;134;135). While 
clinical isolates have been shown to have the ability to generate NETs in vitro, there is to 
date no clear evidence to show whether this phenomena occurs in septic patients, or 
whether this is associated with organ dysfunction or mortality. 
7. Translation of preclinical studies to clinical outcomes 
Despite the success of many therapeutic agents in improving outcome in preclinical studies 
of sepsis, many have failed to demonstrate efficacy in the clinical setting. To illustrate, 
studies investigating the efficacy of anti-TNF therapies (5;5;136;137) and activated protein C 
(APC) were promising in animal studies, but this success failed to translate to clinical 
outcomes (35;73;138). Neutralization of TNF was beneficial in some models of endotoxemia 
challenge with viable gram-negative bacteria (e.g. group B streptococci) (139-145) but in 
other preclinical studies where microorganisms such as Candida, S. pneumoniae, Listeria, or 
mycobacteria were used, neutralizing TNF exacerbated outcome in animals subjected to the 
pathogenic challenge (36;70;136;137;146-149). In complex models of sepsis, no consistent 
harm or benefit was validated and some clinical studies found an increased mortality 
associated with anti-TNF therapy (150;151). Similar to anti-TNF therapy, some preclinical 
studies demonstrated the protective or therapeutic effect of APC (35;73;138) but these results 
failed to translate in some clinical studies (72). The therapeutic efficacy of anti-TNF therapy 
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and APC in preclinical studies is largely influenced by the animal model used. Thus the 
appropriate translation of findings and inferences from preclinical studies to clinical 
outcomes in sepsis remains a heavily debated area. 
7.1. Critical appraisal of preclinical sepsis studies 
Limitations in both the use of animal models and design of experimental studies contribute 
to the poor translation of preclinical animal studies to clinical sepsis. Some limitations are 
inherent to the use of animals to model any clinical condition. It is commonly the case that 
young animals of a specific gender, species, genetic background, and nutritional status 
housed in a pathogen-free, sterile facility unexposed to the natural environment are used (5). 
Many of these elements are tightly controlled to maintain consistency at the expense of 
clinical relevance. However, an attempt at balancing both consistency and clinical relevance 
can be made if the investigator designs treatment groups for different animals (e.g. separate 
treatment groups for females and males, groups for young and aged mice, etc.) given the 
heterogeneity of the sepsis patient population. 
Other limitations may be appropriately addressed by establishing clear research questions 
and implementing an experimental protocol which would adequately investigate these 
questions. For instance, if the objective of an animal study is to test the clinical applicability 
of a therapeutic agent, it would be more clinically relevant if therapies currently used for the 
management of sepsis including the adequate administration of resuscitation fluids, 
antibiotics, and supportive therapies (14) were incorporated into the experimental protocol 
of the animal study. Additionally, the experimental protocol of animal studies can be 
modified to include clinically relevant management procedures such as constant monitoring 
and assessment for hemodynamic parameters, tissue perfusion, or dehydration as would 
occur in clinical sepsis. Other factors which may contribute to the gap between findings in 
experimental and clinical studies include the time at which therapeutic agents are 
administered, the lack of staging of sepsis to reflect disease progression at different 
severities on the sepsis continuum or different patient populations, and the risk of 
experimenter bias in animal studies (5;12) 
7.2. Limitations to the clinical relevance of animal studies 
7.2.1. Age 
It is commonly the case that murine studies of sepsis utilize 8 week-old mice, the 
physiological equivalent of a young adulthood in humans. However, the sepsis patient 
population consists largely of patients over 60 years of age which is not adequately 
represented in sepsis literature using animal models (152). There are limitations to 
examining the true pathophysiology and clinical treatment of a condition which occurs most 
commonly in the aging population when findings are extrapolated from preclinical studies 
using young, healthy mice exclusively. For example, aging is associated with increased 
apoptosis of rapidly dividing epithelial cells of the gut and spleen in animal sepsis (153). 
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This may contribute to the increased mortality in aged septic mice, a factor which would not 
accounted for when using young animals to model sepsis occurring in an aging population. 
The effect of age in sepsis in a clinical setting can be appreciated in the PROWESS trials. 
Substantial difference in absolute risk reduction of mortality were found to be associated 
with age in clinical sepsis (154). Age should be considered in animal studies of sepsis to 
increase the clinical relevance to human sepsis. 
7.2.2. Gender 
In addition to limitations produced by using young animals exclusively, male animals are 
almost exclusively chosen in intra-abdominal sepsis studies which poorly reflects the 
incidence of clinical sepsis in both genders around 40% of which is female (155). Male mice 
are often chosen over females to avoid confounding effects and variables posed by varied 
expression of biomarkers and circulating cells associated with different phases of the estrous 
cycle. For instance, steroid hormones are implicated in the expression of adhesion molecules 
resulting in different peripheral blood leukocyte concentrations and an altered coagulant 
response (156;157). Neutrophil concentrations and response to stimulation also vary 
considerably during different phases of the estrous cycle (158). For consistency, male mice 
are often chosen of sepsis studies, despite the similar occurrence of sepsis in males and 
females however, an investigator should consider, if feasible, treatments with one group for 
each gender of animal used. 
7.2.3. Fluid resuscitation 
The importance of early goal-directed treatment including adequate fluid resuscitation and 
treatment with antibiotics has been thoroughly demonstrated in severe sepsis and septic 
shock (159). Correction of hemodynamic abnormalities and hypovolemia associated with 
sepsis is integral to reducing mortality rates and improving sepsis outcomes. Hypovolemia 
compromises tissue oxygenation due to inadequate blood flow within the microvasculature 
and is the prime cause of organ dysfunction and failure (159). In order to differentiate 
pathology due to sepsis from pathology resulting solely from circulatory decline and lack of 
hemodynamic support, the administration of balanced fluids is crucial. This is supported by 
findings showing significant differences between the hemodynamic profiles of under-
resuscitated animals versus those with adequate supportive fluids, and aggressive fluid 
resuscitation was required to replicate hemodynamic profiles observed in patients with 
severe sepsis (47). In canines with septic shock, animals that received combination therapy 
of antibiotics and cardiovascular support (via fluid resuscitation and dopamine) had a 43% 
improvement in survival rates compared to septic animals treated with either therapy alone 
(160;160). Furthermore, experiments elucidating the effects of various fluid regimes on 
resuscitation in sepsis have demonstrated that lactated Ringer’s crystalloid solution but not 
saline-based solutions reduced sepsis-induced leukocyte recruitment in the liver of mice 
subjected to CLP (161). Based on these studies, an appropriate fluid regime which would 
account for surgical losses and provide adequate hemodynamic support to maintain 
circulatory and cardiovascular function, as would occur in the management of clinical 
sepsis, should be considered in preclinical studies of sepsis (12). 
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7.2.4. Patient heterogeneity 
The human septic population is diverse and highly heterogeneous. Clinical cases of sepsis 
are often much more complex than sepsis induced in animal studies. The diversity of 
infectious agents as well as sites of infection in clinical sepsis are not always reflected in animal 
studies, factors which should be considered in the translation of preclinical to clinical studies. 
For instance, clinical sepsis may result from trauma and subsequent fecal spillage into a sterile 
peritoneum or staphylococcal bacteremia in an elderly patient with congestive heart failure. 
Evidently, animal models like those inducing sepsis via injections of endotoxic bacterial 
components or even live bacteria fail to induce the range of conditions observed in a septic 
patient (5). To decrease this gap, one may choose to consider introducing cormorbidities as 
previously described or other trauma or infectious injuries to animal sepsis models. 
 
Animal Species, genetic background, gender, age, 
nutritional status following insult, 
comorbidities incorporated in model 
Source of Infection Single versus multiple organisms, local 
versus systemic challenge, addition of 
adjuvants, presence and extent of tissue 
damage from challenge 
Intervention Dose and timing of intervention compared 
to septic insult (administered before, 
concurrent with, or following insult) 
Co-interventions Fluid resuscitation, antibiotics, analgesics, 
source removal 
Experimental Design Risk bias (blinding or randomization 
methods are used), assay methodology 
Markers of Outcome Parameters used as markers of outcome 
(choice of biomarker and quantification 
methods, physiological response, 
inflammatory parameters, survival) 
Table 1. Limitations to the Clinical Relevance of Preclinical Studies 
7.3. Summary of limitations 
Factors which limit the translation of preclinical studies to clinical outcomes include the 
following (5): the animal used for experimental studies (species, genetic background, 
gender, age, nutritional status following insult, comorbidities incorporated in model), the 
source of infection (organism, local vs. systemic challenge, adjuvants, tissue damage from 
challenge), dose and timing of intervention (administered before, concurrent with, or 
following insult), co-interventions (fluid resuscitation, antibiotics, analgesics, source 
removal), experimental design (risk bias, blinding, randomization, assay methodology), and 
parameters used as markers of outcome (quantification and choice of biomarker, 
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physiological response, inflammatory parameters, survival) which can significantly alter 
response to treatment. These potential limitations are summarized in Table 1 adapted from 
Marshall et al, 2005.  
7.4. Considerations to improve the translation of preclinical studies to clinical 
outcomes 
It is evident that experimental design greatly influences the findings of both experimental 
and clinical studies in sepsis. One method to increase the transparency, reproducibility, 
consistency, and efficacy of sepsis research is to increase standards for reporting of animal 
sepsis studies. The Consolidated Standards of Reporting Trials (CONSORT 1996, 2001, and 
2010) statement is a rigorous and highly standardized approach to conducting clinical 
research which addresses variability of results due to the study design and reporting of 
clinical trials (162-164). In an attempt to limit the variability in both the use of animal studies 
and reporting of results, Marshall et al. propose that a similar checklist should be required 
for preclinical studies (5). The checklist includes the following variables which should be 
explicitly described and recorded in detailed manner to ease pooling of results from various 
preclinical studies, define a framework from which to understand divergent results, 
improve the consistency of reporting of results, and enhance the reliability of reported 
results. The standards for reporting animal research in bioscience were raised further in 
2010 with the publication of the ARRIVE guidelines, Animals in Research: Reporting In Vivo 
Experiments (165). Below is an adaptation of the Consolidated Standards of Reporting Trials 
Checklist for Preclinical Studies proposed by Marshall et al. in 2005 with descriptions of 
methods by which these reporting standards could be maintained as suggested by Kilkenny 
et al. (Table 2). 
7.4.1. Sepsis definition 
In the design and reporting of a preclinical sepsis study, a basic but crucial aspect that one 
should consider is the very definition of sepsis, the conditions and presentation of which 
differ from one  animal model to another. Clinical sepsis is defined by meeting specific 
criteria which involve inflammatory, hemodynamic, organ dysfunction, and tissue 
perfusion variables. Sepsis is no longer defined solely by changes in physiological 
parameters (e.g. body temperature, heart rate, respiratory rate, and white blood cell count) 
which are common to many other conditions. Likewise, defining sepsis based on levels of 
several biomarkers of inflammation, for instance fails to capture the complexity of 
cardiovascular, hormonal, metabolic, innate and adaptive immune changes which occur in 
this heterogeneous condition. Although it would be helpful to document changes in 
biomarkers and physiological parameters (e.g. heart rate, etc.), current preclinical studies 
are limited as the criteria which define sepsis (and the severity) in various animals have 
not been clearly elucidated. There is currently no consensus over the physiological 
parameters, levels of biomarkers, or variables of end organ health which would indicate 
sepsis in an animal although these parameters are much more clearly outlined by clinical 
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sepsis definition guidelines (1). This limitation will need to be addressed in future 
preclinical sepsis studies. Other parameters which may be informative of the septic 
condition in animals include appearance (perfusion of mucous membranes), urine 
production, and bacterial cultures from the blood, peritoneal fluid, and local site of 
infection, which may be considered in the design of animal studies. Successful animal 
studies should establish a clear definition of the conditions which would indicate a septic 
animal, explicitly defining the severity of disease induced as part of the study protocol 
(167). 
 
Sepsis Definition Clear sepsis definition as indicators of 
sepsis, severe sepsis, or septic shock in the 
animal used (166) 
Animal Species, strain, genetic background, gender, 
age, weight, handling, housing, feeding 
conditions 
Experimental Design Method of sepsis induction (details which 
indicate severity), intervention (timing and 
dose), experimental methodology, controls 
included, randomization methods, blinding 
of experimenter 
Analytic Plan Primary and secondary endpoints, power 
calculations for sample size determination, 
intention-to-treat analysis, criteria for 
animals excluded from studies (substitute 
endpoints) 
Co-Interventions Resuscitation fluids, antibiotics, source 
removal, feeding 
Results Flowchart of included and excluded 
animals, establish mortality rates in studies 
conducted 
Table 2. Checklist for the Reporting of Animal Studies  
7.4.2. Experimental design 
In the interests of reproducibility and reliability, the method of sepsis induction, 
intervention (timing and dose), experimental protocol, inclusion of proper controls, 
randomization methods, and methods of experimenter blinding should be documented in 
detail. Although experimental methodologies are commonly recorded, there is a 
significant lack of attention to reduce experimenter bias by randomization and blinding, 
despite the confounding effects recently addressed in a systematic review of literature of 
studies using animal sepsis models. It was observed that only 2% of systematic reviews 
and meta-analyses appraised the risk of bias or clinical relevance of the underlying animal 
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research despite a significant proportion of the literature extrapolating results from animal 
studies to clinical sepsis (168). In one review of studies using animal models, more than 
80% of research papers surveyed did not report the use of methods to minimize the risk of 
bias by the investigator (165;169). To improve the translation of inferences and findings 
from experimental sepsis to clinical sepsis in future studies, one should consider reducing 
the effects of experimenter bias by randomizing animals in the treatment groups of the 
study and blinding the experimenter to the intervention provided given that 
implementation of these elements would not compromise the protocol or results of the 
study (5;166;167). 
7.4.3. Randomization 
In the absence of randomization, the results of clinical and animal studies may be 
unintentionally biased by factors which may influence study outcomes. Nonrandomized 
clinical studies have frequently shown a larger treatment effect than randomized control 
trials, an effect which should be studied and addressed in animal studies (168;170-173). 
Randomization involves taking proactive measures in assigning subjects to a treatment or 
control group in studies testing the efficacy of a potential treatment drug versus a placebo 
control or potential treatment drug versus a pre-existing treatment (167;173). The systematic 
randomization of subjects or animals minimizes allocation or selection bias by eliminating 
influences from unknown or known prognostic variables (like the hemodynamics in septic 
and nonseptic animals) which may influence the response to treatment, mortality, or 
outcome, unduly producing biased results in a study (166;170-172). Randomization also 
ensures that protocols and procedures are conducted consistently and systematically in 
treatment and control groups. Elements of animal studies where randomization may offer 
an efficacious benefit include the procedure to induce sepsis (preventing unintentional bias 
by variations in sepsis severity), treatment (consistent timing, route, and method of 
administering treatments or controls), monitoring of subjects following sepsis induction and 
treatment, and resuscitation procedures of the study groups (169;173). 
Although various methods of randomization have been established and recommended for 
different clinical trials, consensus and literature on randomization in pre-clinical and 
experimental studies are lacking. Simple randomization methods such as the "repeated fair 
coin-tossing" have been recommended for large clinical studies (n > 200), but are inadequate 
for studies with small samples sizes like experimental animal studies (167;173). Restricted 
randomization methods like permutated-block randomization where allocation ratios are 
used to specify the number of subjects in each group (or ratio of subjects in one treatment 
group to another) (170-172) successfully address this issue, but restricted randomization 
methods have not been validated in animal studies. Given that the risk of allocation and 
selection bias have been shown to unduly influence the results of clinical studies and that 
randomization and blinding have successfully minimized these risks, it is crucial that the 
same level of criticism and caution be applied in the experimental design and conducting of 
experimental studies by addressing these risks (167;170-173). 
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7.4.4. Blinding 
In addition to randomization, blinding of investigators also minimizes the risk of bias at 
many levels of the preclinical study. Blinding decreases differential treatment of animals in 
the study groups (more intensive monitoring or closer supervision of one treatment group 
over another) to unintentional biases in analyzing data and adjudicating outcomes (5;166). 
For instance, markers of disease severity or mortality outcome such as organ histology may 
be interpreted in a biased manner in an untreated control group versus the treated group if 
the investigator is not blinded to the treatment received (169). Likewise, marginal findings 
may be analyzed in a biased manner when interpretation of the outcome marker is 
subjective. In studies where substitute endpoints are used (such is the case when mortality is 
not used as endpoints for ethical reasons), blinding reduces the chance of experimenters 
prolonging the time to endpoint (in an attempt to establish a therapeutic effect when one 
does not exist) or decreasing the time to a substitute endpoint or even excluding animals (if 
unexpected results are observed in either treatment or control groups) (165;167;170;172). 
Blinding of the investigator to the treatment or control substance received minimizes the 
risk of experimenter bias. 
7.4.5. Analytic plan 
The analytic plan should be described in detail such that the procedure is reproducible by 
others and variations in models used by other investigators can be appreciated (e.g. size and 
number of enterotomies and location of ligature in a CLP model) when comparing various 
preclinical studies (5). Primary and secondary endpoints of the study should be clearly 
outlined, whether they are to determine the efficacy of a potential therapy, improve 
prognosis, or diagnosis of sepsis. If the primary objective is to investigate a potential 
therapy, endpoints and markers of outcome of the animal study should also be clinically 
relevant (166;173;174). The measurement of outcome should also appropriately reflect markers 
relevant to the potential therapy being tested. For example, the coagulant state of the animals 
should be measured if the drug being tested acts via its anticoagulant effects. While mortality 
is the most informative marker of outcome in clinical sepsis, organ health and dysfunction are 
useful surrogate markers of outcome due to their relevance to clinical sepsis (173). 
7.4.6. Power calculations 
In studies elucidating the therapeutic potential of a compound, power calculations can be 
used to reliably determine the sample size required to show that an effect is associated with 
treatment as well as exclude an effect when none exists (5). The magnitude of a treatment 
effect is most commonly expressed as the relative risk reduction (RRR, RRR = [1-(X/Y)] x 100 
where Y is the proportion of animals that expired in the treatment group and X is the 
proportion of animals that expired in the control group (175). Given that mortality (and 
therefore the power of the study) will be altered should any subjects be excluded, the 
exclusion of subjects should only occur if subjects meet pre-established criteria. 
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7.4.7. Exclusion criteria 
As in clinical studies, conditions under which subjects will be excluded should be clearly 
outlined before the animal study (169). The study should account for all animals, including 
those that do not complete the experimental protocol and observations and reasons for 
excluded animals should be appropriately documented. This is important to determine 
whether prognosis independent of the treatment may in actuality be related to the  
exclusion of certain subjects (5;174). Data should also be recorded and kept for subjects 
excluded from the study for any post-hoc analyses, standards which are expected of clinical 
studies. 
7.4.8. Animal welfare 
Many animal ethics and welfare committees are preventing the use of mortality as an 
endpoint and encouraging the use of surrogate markers of death. However, investigators 
and funding agencies are critical of such studies which do not use changes in mortality as a 
measure of therapeutic efficacy. There is currently no consensus nor scientific validation of 
clinically relevant, reliable substitute markers of death in septic animals (5;174). Moreover, 
there is concern over the use of analgesics and anaesthetics which have been shown to 
interfere with components in the natural progression of sepsis and even exert protective, 
anti-inflammatory effects. For example, in vivo and in vitro studies have elucidated that 
pentobarbital significantly reduces the LPS-induced inflammatory response by suppressing 
TNF α mRNA and protein expression by NF-κB and p38 MAP kinase (176). The concern 
over analgesics and anaesthetics Interfering with disease progression and treatment 
response may cause some reluctance towards the appropriate use of analgesics and 
anaesthetics in preclinical studies. Although scientific concern is warranted, these findings 
highlight the importance of considering drug effects and incorporating them into the 
experimental design, as it should be noted that analgesics and anaesthetics are clinically 
relevant to treatment and management of the septic patient, and from the standpoint of 
relevance (not to mention from an ethical standpoint), should not be excluded in animal 
studies. To improve clinical relevance and translation of studies utilizing experimental 
models, the appropriate use of these drugs with further understanding of their effects 
should be integrated rather than avoided in preclinical studies of sepsis (5;165). 
7.5. Recommendations for a thorough validation of therapeutic efficacy in 
preclinical studies 
Given the potential limitations of preclinical studies when designing preclinical studies with 
potential clinical applications, one should take a critical approach when validating the 
therapeutic efficacy of a potential drug in preclinical studies. Recommendations for 
conducting preclinical studies with clinical applications will be provided with the intent to 
address the concerns raised previously. Literature by Marshall et al. suggest that early proof 
 Sepsis – An Ongoing and Significant Challenge 58 
of concept studies should 1) delineate a potential pathological role for the target in question 
by quantifying its increases in a simple acute model like endotoxemia or bacteremia (LPS or 
E. coli challenge) and 2) demonstrate that attenuating such target may improve outcome or 
offer some therapeutic benefit by a measurable decrease in harmful effects of the initial 
challenge or insult (5;165;174). If a proof of concept can be established, time course studies 
should be conducted to determine if the potential treatment offers therapeutic effects if 
administered before, during the progression of, or after the insult in both simple acute and 
complex models (e.g. LPS challenge and CLP). Experimental methodology and design of 
further studies should consider the results of studies on targets with similar biological or 
pathophysiological effects. Any adverse effects of the intervention, like impairment of the 
host’s natural anti-microbial immune function or further dysregulation of the coagulant 
state should be determined in a high-risk model using live organisms as the challenges. 
(5;174) Moreover, the systemic physiological and biological responses to the therapeutic 
intervention (e.g. cardiac output, oxygenation, glomerular filtration) should be determined 
in a large animal model, given the limitations of small rodent models of sepsis. Interventions 
used in the management of clinical sepsis such as fluid resuscitation, ventilatory support, 
and hemodynamic monitoring, can be incorporated into the study design of preclinical trials 
using large animal models (5). 
8. Goals for the future of experimental sepsis research 
Goals for the future use of experimental sepsis models ought to focus on improving the 
relevance, translation, and applicability of results and inferences from animal studies to 
what is observed clinically. This requires consideration of the limitations of current sepsis 
models described such as considering age, gender, genetic background, nutritional status, 
and the environment of the housing facility, incorporating cormorbidities and supportive 
therapies which may be clinically relevant, and finally addressing the risk of bias by 
randomization and blinding methods in preclinical studies of sepsis. 
Author details 
Safiah Mai, Momina Khan and Patricia Liaw* 
McMaster University, Canada 
David Braley Research Institute, Canada 
Alison Fox-Robichaud* 
McMaster University, Canada 
David Braley Research Institute, Canada 
Hamilton Health Sciences, Canada 
                                                                 
* on behalf of the Canadian Critical Care Translational Biology Group (CCCTBG) 
 
Experimental Sepsis Models 59 
9. References 
[1] Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 
SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care 
Med 2003, 31:1250-6. 
[2] Namas R, Zamora R, Namas R, An G, Doyle J, Dick TE, et al. Sepsis: Something old, 
something new, and a systems view. J Crit Care 2012, 27:314-11. 
[3] Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock--a review of laboratory 
models and a proposal. J Surg Res 1980, 29:189-201. 
[4] Deitch EA. Rodent models of intra-abdominal infection. Shock 2005, 24 Suppl 1:19-23. 
[5] Marshall JC, Deitch E, Moldawer LL, Opal S, Redl H, Poll Tvd. Preclinical Models of 
Shock and Sepsis: What Can They Tell Us? Shock 2005, 24 Suppl 1:1-6. 
[6] Clowes GH, Jr., Zuschneid W, Turner M, Blackburn G, Rubin J, Toala P, et al. 
Observations on the pathogenesis of the pneumonitis associated with severe infections 
in other parts of the body. Ann Surg 1968, 167:630-50. 
[7] Sloane DR, Clowes GJ. Traumatic intramural haematoma of the duodenum. Med J Aust 
1968, 2:1184-5. 
[8] Wright NG, Cornwell HJ, Thompson H. Canine adenovirus nephritis. J Small Anim 
Pract 1971, 12:657-64. 
[9] Wright NG, Thompson H, Cornwell HJ. Canine adenovirus pneumonia. Res Vet Sci 
1971, 12:162-7. 
[10] Ryan CJ, Benjamin IS, Blumgart LH. Portacaval transposition in the rat: a new 
technique and its effects on liver and body weight. Br J Surg 1974, 61:224-8. 
[11] Rittirsch D, Huber-Lang MS, Flierl MA, Ward PA. Immunodesign of experimental 
sepsis by cecal ligation and puncture. Nat Protocols 2008, 4:31-6. 
[12] Dejager L, Pinheiro I, Dejonckheere E, Libert C. Cecal ligation and puncture: the gold 
standard model for polymicrobial sepsis? Trends Microbiol 2011, 19:198-208. 
[13] Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996, 24:1125-8. 
[14] Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus 
DC, Brun-Buisson C, et al. Surviving Sepsis Campaign: International guidelines for 
management of severe sepsis and septic shock. Intensive Care Med 2008, 34:17-60. 
[15] Remick DG, Newcomb DE, Bolgos GL, Call DR. Comparison of the mortality and 
inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation 
and puncture. Shock 2000, 13:110-6. 
[16] Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat 
Med 2003, 9:517-24. 
[17] Riedemann NC, Guo RF, Hollmann TJ, Gao Hong, Neff TA, Reuben JS, et al. Regulatory 
role of C5a in LPS-induced IL-6 production by neutrophils during sepsis. The FASEB 
Journal 2004, 18:370-2. 
[18] Huber-Lang M, Sarma VJ, Lu KT, McGuire SR, Padgaonkar VA, Guo RF, et al. Role of 
C5a in multiorgan failure during sepsis. J Immunol 2001, 166:1193-9. 
 Sepsis – An Ongoing and Significant Challenge 60 
[19] Huber-Lang MS, Riedeman NC, Sarma JV, Younkin EM, McGuire SR, Laudes IJ, et al. 
Protection of innate immunity by C5aR antagonist in septic mice. FASEB J 2002, 
16:1567-74. 
[20] Czermak BJ, Sarma V, Pierson CL, Warner RL, Huber-Lang M, Bless NM, et al. 
Protective effects of C5a blockade in sepsis. Nat Med 1999, 5:788-92. 
[21] Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. The sepsis seesaw: tilting 
toward immunosuppression. Nat Med 2009, 15:496-7. 
[22] Muenzer JT, Davis CG, Chang K, Schmidt RE, Dunne WM, Coopersmith CM, et al. 
Characterization and modulation of the immunosuppressive phase of sepsis. Infect 
Immun 2010, 78:1582-92. 
[23] Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation 
in sepsis. Nat Rev Immunol 2006, 6:813-22. 
[24] Maier S, Traeger T, Entleutner M, Westerholt A, Kleist B, Huser N, et al. Cecal ligation 
and puncture versus colon ascendens stent peritonitis: two distinct animal models for 
polymicrobial sepsis. Shock 2004, 21:505-11. 
[25] Schabbauer G. Polymicrobial sepsis models: CLP versus CASP. Drug Discovery Today: 
Disease Models 2012, 9:e17-e21. 
[26] Zantl N, Uebe A, Neumann B, Wagner H, Siewert JR, Holzmann B, et al. Essential Role 
of Gamma Interferon in Survival of Colon Ascendens Stent Peritonitis, a Novel Murine 
Model of Abdominal Sepsis. Infection and Immunity 1998, 66:2300-9. 
[27] Buras JA, Holzmann B, Sitkovsky M. Animal Models of sepsis: setting the stage. Nat 
Rev Drug Discov 2005, 4:854-65. 
[28] Traeger T, Mikulcak M, Eipel C, Abshagen K, Diedrich S, Heidecke CD, et al. Kupffer 
cell depletion reduces hepatic inflammation and apoptosis but decreases survival in 
abdominal sepsis. Eur J Gastroenterol Hepatol 2010 Sep, 22:1039-49. 
[29] Emmanuilidis K, Weighardt H, Maier S, Gerauer K, Fleischmann T, Zheng XX, et al. 
Critical role of Kupffer cell-derived IL-10 for host defense in septic peritonitis. J 
Immunol 2001, 167:3919-27. 
[30] Hammer M, Echtenachter B, Weighardt H, Jozefowski K, Rose-John S, Mannel DN, et 
al. Increased inflammation and lethality of Dusp1-/- mice in polymicrobial peritonitis 
models. Immunology 2010, 131:395-404. 
[31] Daubeuf B, Mathison J, Spiller S, Hugues S, Herren S, Ferlin W, et al. TLR4/MD-2 
monoclonal antibody therapy affords protection in experimental models of septic 
shock. J Immunol 2007, 179:6107-14. 
[32] Weighardt H, Kaiser-Moore S, Vabulas RM, Kirschning CJ, Wagner H, Holzmann B. 
Cutting edge: myeloid differentiation factor 88 deficiency improves resistance against 
sepsis caused by polymicrobial infection. J Immunol 2002, 169:2823-7. 
[33] Markus E, Traeger T, Westerholt A, Holzmann B, Stier A, Pfeffer K, Maier S, Heidecke 
CD. Impact of interleukin-12, oxidative burst, and iNOS on the survival of murine fecal 
peritonitis. International Journal of Colorectal Disease 2006, 21:64-70. 
 
Experimental Sepsis Models 61 
[34] Yuan Y, Ren J, Wu X, Cao S, Li J. Exogenous C3 postpones complement exhaustion and 
confers organ protection in murine sepsis. J Surg Res 2011, 168:e87-e94. 
[35] Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, Mosnier LO, et al. 
Endotoxemia and sepsis mortality reduction by non-anticoagulantГÇôactivated protein 
C. The Journal of Experimental Medicine 2007, 204:2439-48. 
[36] Echtenacher B, Falk W, M+ñnnel DN, Krammer PH. Requirement of endogenous tumor 
necrosis factor/cachectin for recovery from experimental peritonitis. The Journal of 
Immunology 1990, 145:3762-6. 
[37] Ebach DR, Riehl TE, Stenson WF. Opposing effects of tumor necrosis factor receptor 1 
and 2 in sepsis due to cecal ligation and puncture. Shock 2005, 23:311-8. 
[38] Moreno SE, Alves-Filho JC, Alfaya TM, da Silva JS, Ferreira SH, Liew FY. IL-12, but not 
IL-18, is critical to neutrophil activation and resistance to polymicrobial sepsis induced 
by cecal ligation and puncture. J Immunol 2006, 177:3218-24. 
[39] Michie HR. The value of animal models in the development of new drugs for the 
treatment of the sepsis syndrome. Journal of Antimicrobial Chemotherapy 1998, 41 
Suppl 1:47-9. 
[40] Guckian JC, Morrey BF, Kirby HB. Role of Lysosomes and Cathepsin Inhibitor in 
Plasma during Pneumococcal Infection. The Journal of Infectious Diseases 1970, 
122:290-302. 
[41] Chiavolini D, Pozzi G, Ricci S. Animal Models of Streptococcus pneumoniae Disease. 
Clinical Microbiology Reviews 2008, 21:666-85. 
[42] Matute-Bello G, Frevert C, Kajikawa O, Skerrett S, Goodman R, Park D, et al. Septic 
Shock and Acute Lung Injury in Rabbits with Peritonitis. American Journal of 
Respiratory and Critical Care Medicine 2001, 163:234-43. 
[43] Guckian JC. Coagulopathy in Experimental Sepsis with Streptococcus pneumoniae in 
Rabbits: Effect of Drug Therapy and Splenectomy. Journal of Infectious Diseases 1976, 
134:150-7. 
[44] Natanson C, Fink MP, Ballantyne HK, MacVittie TJ, Conklin JJ, Parrillo JE. Gram-
negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a 
canine model that simulates human septic shock. J Clin Invest 1986, 78:259-70. 
[45] Nagy S, Tárnoky K TLBMKG. A canine model of hyperdynamic sepsis induced by 
intestinal ischemia. Acta Physiol Hung 1990, 75:303-20. 
[46] Song R, Kim J, Yu D, Park C, Park J. Kinetics of IL-6 and TNF-+¦ changes in a canine 
model of sepsis induced by endotoxin. Veterinary Immunology and Immunopathology 
2012, 146:143-9. 
[47] Zanotti-Cavazzoni SL, Goldfarb RD. Animal Models of-áSepsis. Crit Care Clin 2009, 
25:703-19. 
[48] Reilly PM, Wilkins KB, Fuh KC, Haglund U, Bulkley GB. The mesenteric hemodynamic 
response to circulatory shock: an overview. Shock 2001, 15:329-43. 
[49] Fink MP, Heard SO. Laboratory models of sepsis and septic shock. Journal of Surgical 
Research 1990 Aug, 49:186-96. 
 Sepsis – An Ongoing and Significant Challenge 62 
[50] Spapen H, Zhang H, Wisse E, Baekeland M, Seynaeve C, Eddouks M, et al. The 21-
Aminosteroid U74389G Enhances Hepatic Blood Flow and Preserves Sinusoidal 
Endothelial Cell Function and Structure in Endotoxin-Shocked Dogs. Journal of Surgical 
Research 1999, 86:183-91. 
[51] Cohen R, Hassell A, Marzouk K, Marini C, Liush S, Scharf S. Renal Effects of Nitric 
Oxide in Endotoxemia. American Journal of Respiratory and Critical Care Medicine 
2001, 164:1890-5. 
[52] Ji MH, Yang JJ, Wu J, Li RQ, Li GM, Fan YX, et al. Experimental sepsis in pigs- effects of 
vasopressin on renal, hepatic, and intestinal dysfunction. Ups J Med Sci 2012, 117: 257-
63. 
[53] Azevedo LCP, Park M, Noritomi DT, Maciel AT, Brunialti MK, Salomúo R. 
Characterization of an animal model of severe sepsis associated with respiratory 
dysfunction. Clinics 2007, 62:491-8. 
[54] Luiking YC, Poeze M, Ramsay G, Deutz NEP. The Role of Arginine in Infection and 
Sepsis. Journal of Parenteral and Enteral Nutrition 2005, 29:S70-S74. 
[55] Allen EM, Rowin M, Pappas JB, Vernon DD, Dean JM. Hemodynamic effects of N-
acetylamrinone in a porcine model of group B streptococcal sepsis. Drug Metabolism 
and Disposition 1996, 24:1028-31. 
[56] Greif WM, Forse RA. Interventions to improve cardiopulmonary hemodynamics during 
laparoscopy in a porcine sepsis model. Journal of the American College of Surgeons 
1999, 189:450-8. 
[57] Kato T, Hussein MH, Sugiura T, Suzuki S, Fukuda S, Tanaka T, et al. Development and 
Characterization of A Novel Porcine Model of Neonatal Sepsis. Shock 2004, 21:329-35. 
[58] Ertmer C, Kampmeier TG, Rehberg S, Morelli A, K+Âhler G, Lange M, et al. Effects of 
balanced crystalloid vs. 0.9% saline-based vs. balanced 6% tetrastarch infusion on renal 
function and tubular integrity in ovine endotoxemic shock*. Critical Care Medicine 
2011, 39:783-92. 
[59] Noda H, Noshima S, Nakazawa H, Meyer J, Herndon DN, Redl H, et al. Left ventricular 
dysfunction and acute lung injury induced by continuous administration of endotoxin 
in sheep. Shock 1994, 1:291-8. 
[60] Traber DL, Herndon DN, Stein MD, Traber LD, Flynn JT, Niehaus GD. The pulmonary 
lesion of smoke inhalation in an ovine model. Circ Shock 1986, 18:311-23. 
[61] Soejima K, Schmalstieg FC, Sakurai H, Traber LD, Traber DL. Pathophysiological 
analysis of combined burn and smoke inhalation injuries in sheep. American Journal of 
Physiology - Lung Cellular and Molecular Physiology 2001, 280:L1233-L1241. 
[62] Shirani KZ, Pruitt B, Mason ADJ. The Influence of Inhalation Injury and Pneumonia on 
Burn Mortality. Annals of Surgery 1987, 205:82-7. 
[63] Traber DL, Herndon DN, Stein MD, Traber LD, Flynn JT, Niehaus GD. The pulmonary 
lesion of smoke inhalation in an ovine model. Circ Shock 2012, 18:311-23. 
 
Experimental Sepsis Models 63 
[64] Maybauer MO, Maybauer DM, Traber LD, Westphal M, Enkhbaatar P, Morita N, et al. 
Gentamicin Improves Hemodynamics in Ovine Septic Shock After Smoke Inhalation 
Injury. Shock 2005, 24:226-31 
[65] Maybauer DM, Maybauer MO, Szab+¦ C, Cox RA, Westphal M, Kiss L, et al. The 
Peroxynitrite Catalyst WW-85 Improves Pulmonary Function in Ovine Septic Shock. 
Shock 2011, 35:148-55. 
[66] Calzavacca P, Ramchandra R, Booth L, Bellomo R, May CN. Cardiovascular effects of 
beta-blockade in a sheep model of severe sepsis. Critical Care 2011, 15 Suppl 3:P36. 
[67] Lange M, Ertmer C, Rehberg S, Morelli A, K+Âhler G, Kampmeier T, et al. Effects of 
two different dosing regimens of terlipressin on organ functions in ovine endotoxemia. 
Inflammation Research 2011, 60:429-37. 
[68] Su F, Huang H, He X, Simuen D, Xie J, Orbach A, et al. Effects of a Novel Anticoagulant 
Compound (TV7130) in an Ovine Model of Septic Shock. Shock 2010, 34:622-7. 
[69] Waerhaug K, Kuklin V, Kirov M, Sovershaev M, Langbakk B, Ingebretsen O, et al. 
Recombinant human activated protein C attenuates endotoxin-induced lung injury in 
awake sheep. Critical Care 2008, 12:R104. 
[70] Redl H, Bahrami S. Large Animal Models: Baboons for Trauma, Shock, and Sepsis 
Studies. Shock 2005, 24:88-93. 
[71] Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, et al. Extracellular 
histones are major mediators of death in sepsis. Nat Med 2009, 15:1318-21. 
[72] Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al. 
Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012, 366:2055-64. 
[73] Taylor FB, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C 
prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. 
J Clin Invest 1987, 79:918-25. 
[74] Shah BR, Hux JE. Quantifying the Risk of Infectious Diseases for People With Diabetes. 
Diabetes Care 2003, 26:510-3. 
[75] Jacober SJ, Sowers JR. An Update on Perioperative Management of Diabetes. Arch 
Intern Med 1999, 159:2405-11. 
[76] Browne JA, Cook C, Pietrobon R, Bethel MA, Richardson WJ. Diabetes and Early 
Postoperative Outcomes Following Lumbar Fusion. Spine 2007, 32:2214-9. 
[77] Kornum JB, Thomsen RW, Riis A, Lervang HH, Sch+©nheyder HC, S+©rensen HT. 
Diabetes, Glycemic Control, and Risk of Hospitalization With Pneumonia. Diabetes 
Care 2008, 31:1541-5. 
[78] Moss M. Epidemiology of Sepsis: Race, Sex, and Chronic Alcohol Abuse. Clinical 
Infectious Diseases 2005, 41 Suppl 7:S490-S497. 
[79] Jacob A, Steinberg ML, Yang J, Dong W, Ji Y, Wang P. Sepsis-induced inflammation in 
exacerated in an animal model of type II diabetes. Int J Cli Exp Med, 1:22-31. 
[80] Edwards MS, Fuselier PA. Enhanced susceptibility of mice with streptozotocin-induced 
diabetes to type II group B streptococcal infection. Infection and Immunity 1983, 39:580-
5. 
 Sepsis – An Ongoing and Significant Challenge 64 
[81] Yamashiro S, Kawakami K, Uezu K, Kinjo T, Miyagi K, Nakamura K, et al. Lower 
expression of Th1-related cytokines and inducible nitric oxide synthase in mice with 
streptozotocin-induced diabetes mellitus infected with Mycobacterium tuberculosis. 
Clinical & Experimental Immunology 2005, 139:57-64. 
[82] Graves DT, Naguib G, Lu H, Leone C, Hsue H, Krall E. Inflammation is More Persistent 
in Type 1 Diabetic Mice. Journal of Dental Research 2005, 84:324-8. 
[83] Strandberg L, Verdrengh M, Enge M, Andersson N, Amu S, +ûnnheim K, et al. Mice 
Chronically Fed High-Fat Diet Have Increased Mortality and Disturbed Immune 
Response in Sepsis. PLoS ONE 2009, 4:e7605. 
[84] Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive 
Care Medicine 2000, 26 Suppl 1:S64-S74. 
[85] Wagenlehner FME, Pilatz A, Weidner W. UrosepsisГÇöfrom the view of the urologist. 
International Journal of Antimicrobial Agents 2011, 38 Suppl 0:51-7. 
[86] Hagberg L, Engberg I, Freter R, Lam J, Olling S, Svanborg Ed+®n C. Ascending, 
unobstructed urinary tract infection in mice caused by pyelonephritogenic Escherichia 
coli of human origin. Infection and Immunity 1983, 40:273-83. 
[87] Reid G, Chan RC, Bruce AW, Costerton JW. Prevention of urinary tract infection in rats 
with an indigenous Lactobacillus casei strain. Infection and Immunity 1985, 49:320-4. 
[88] Stewart D, Fulton WB, Wilson C, Monitto CL, Paidas CN, Reeves RH, et al. Genetic 
Contribution to the Septic Response in A Mouse Model. Shock 2002, 18:342-7. 
[89] Wang H, Laskowitz DT, Sullivan PM, Christensen DJ. APOE genotype affects outcome 
in a murine model of sepsis: implications for a new treatment strategy. Anaesthesia and 
Intensive Care 2009, 37:38-45. 
[90] Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia 
and arterial lesions in mice lacking apolipoprotein E. Science 1992, 258:468-71. 
[91] Grainger DJ, Reckless J, McKilligin E. Apolipoprotein E Modulates Clearance of 
Apoptotic Bodies In Vitro and In Vivo, Resulting in a Systemic Proinflammatory State 
in Apolipoprotein E-Deficient Mice. The Journal of Immunology 2004, 173:6366-75. 
[92] de Bont N, Netea MG, Demacker PNM, Verschueren I, Kullberg BJ, van Dijk KW, et al. 
Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and Klebsiella 
pneumoniae infection. Journal of Lipid Research 1999, 40:680-5. 
[93] Haraguchi G, Kosuge H, Maejima Y, Suzuki JI, Imai T, Yoshida M, et al. Pioglitazone 
reduces systematic inflammation and improves mortality in apolipoprotein E knockout 
mice with sepsis. Intensive Care Medicine 2008, 34:1304-12. 
[94] Gao XP, Liu Q, Broman M, Predescu D, Frey RS, Malik AB. Inactivation of CD11b in a 
mouse transgenic model protects against sepsis-induced lung PMN infiltration and 
vascular injury. Physiological Genomics 2005, 21:230-42. 
[95] Wu Z, Sawamura T, Kurdowska AK, Ji HL, Idell S, Fu J. LOX-1 Deletion Improves 
Neutrophil Responses, Enhances Bacterial Clearance, and Reduces Lung Injury in a 
Murine Polymicrobial Sepsis Model. Infection and Immunity 2011, 79:2865-70. 
 
Experimental Sepsis Models 65 
[96] Kaisho T, Akira S. Dendritic-cell function in Toll-like receptor- and MyD88-knockout 
mice. Trends in immunology 2001, 22:78-83.  
[97] Zhang D, Zhang G, Hayden MS, Greenblatt MB, Bussey C, Flavell RA, et al. A Toll-like 
Receptor That Prevents Infection by Uropathogenic Bacteria. Science 2004, 303:1522-6. 
[98] Sugawara I, Yamada H, Li C, Mizuno S, Takeuchi O, Akira S. Mycobacterial infection in 
TLR2 and TLR6 knockout mice. Microbiol Immunol 2003, 47:327-36. 
[99] Tschop J, Nogueiras R, Haas-Lockie S, Kasten KR, Castaneda TR, Huber N, et al. CNS 
Leptin Action Modulates Immune Response and Survival in Sepsis. The Journal of 
Neuroscience 2010, 30:6036-47. 
[100] Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. 
Neutrophil extracellular traps kill bacteria. Science 2004, 303:1532-5. 
[101] Papayannopoulos V, Zychlinsky A. NETs: a new strategy for using old weapons. 
Trends Immunol 2009, 30:513-21. 
[102] Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, et al. Novel cell death 
program leads to neutrophil extracellular traps. J Cell Biol 2007, 176:231-41. 
[103] Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and 
myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol 
2010, 191:677-91. 
[104] Remijsen Q, Kuijpers TW, Wirawan E, Lippens S, Vandenabeele P, Vanden Berghe T. 
Dying for a cause: NETosis, mechanisms behind an antimicrobial cell death modality. 
Cell Death Differ 2011, 18:581-8. 
[105] Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of 
necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010, 11:700-14. 
[106] Bruns S, Kniemeyer O, Hasenberg M, Aimanianda V, Nietzsche S, Thywissen A, et al. 
Production of extracellular traps against Aspergillus fumigatus in vitro and in infected 
lung tissue is dependent on invading neutrophils and influenced by hydrophobin 
RodA. PLoS Pathog 2010, 6:e1000873. 
[107] Urban CF, Reichard U, Brinkmann V, Zychlinsky A. Neutrophil extracellular traps 
capture and kill Candida albicans yeast and hyphal forms. Cell Microbiol 2006, 8:668-76. 
[108] Urban CF, Ermert D, Schmid M, Abu-Abed U, Goosmann C, Nacken W, et al. 
Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex 
involved in host defense against Candida albicans. PLoS Pathog 2009, 5:e1000639. 
[109] Bianchi M, Hakkim A, Brinkmann V, Siler U, Seger RA, Zychlinsky A, et al. 
Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood 
2009, 114:2619-22. 
[110] Springer DJ, Ren P, Raina R, Dong Y, Behr MJ, McEwen BF, et al. Extracellular fibrils 
of pathogenic yeast Cryptococcus gattii are important for ecological niche, murine 
virulence and human neutrophil interactions. PLoS One 2010, 5:e10978. 
[111] Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. 
Impairment of neutrophil extracellular trap degradation is associated with lupus 
nephritis. Proc Natl Acad Sci U S A 2010, 107:9813-8. 
 Sepsis – An Ongoing and Significant Challenge 66 
[112] Buchanan JT, Simpson AJ, Aziz RK, Liu GY, Kristian SA, Kotb M, et al. DNase 
expression allows the pathogen group A Streptococcus to escape killing in neutrophil 
extracellular traps. Curr Biol 2006, 16:396-400. 
[113] Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. 
Neutrophil extracellular traps kill bacteria. Science 2004, 303:1532-5. 
[114] Beiter K, Wartha F, Albiger B, Normark S, Zychlinsky A, Henriques-Normark B. An 
endonuclease allows Streptococcus pneumoniae to escape from neutrophil extracellular 
traps. Curr Biol 2006, 16:401-7. 
[115] Guimaraes-Costa AB, Nascimento MT, Froment GS, Soares RP, Morgado FN, 
Conceicao-Silva F, et al. Leishmania amazonensis promastigotes induce and are killed 
by neutrophil extracellular traps. Proc Natl Acad Sci U S A 2009, 106:6748-53. 
[116] Ramos-Kichik V, Mondragon-Flores R, Mondragon-Castelan M, Gonzalez-Pozos S, 
Muniz-Hernandez S, Rojas-Espinosa O, et al. Neutrophil extracellular traps are induced 
by Mycobacterium tuberculosis. Tuberculosis (Edinb ) 2009, 89:29-37. 
[117] McCormick A, Heesemann L, Wagener J, Marcos V, Hartl D, Loeffler J, et al. NETs 
formed by human neutrophils inhibit growth of the pathogenic mold Aspergillus 
fumigatus. Microbes Infect 2010, 12:928-36. 
[118] Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, et al. Platelet 
TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat 
Med 2007, 13:463-9. 
[119] Martinez VF, Balada E, Ordi-Ros J, Vilardell-Tarres M. DNase 1 and systemic lupus 
erythematosus. Autoimmun Rev 2008, 7:359-63. 
[120] Tew MB, Johnson RW, Reveille JD, Tan FK. A molecular analysis of the low serum 
deoxyribonuclease activity in lupus patients. Arthritis Rheum 2001, 44:2446-7. 
[121] Balada E, Ordi-Ros J, Hernanz S, Villarreal J, Cortes F, Vilardell-Tarres M, et al. 
DNASE I mutation and systemic lupus erythematosus in a Spanish population: 
comment on the article by Tew et al. Arthritis Rheum 2002, 46:1974-6. 
[122] Bodano A, Gonzalez A, Balada E, Ordi J, Carreira P, Gomez-Reino JJ, et al. Study of 
DNASE I gene polymorphisms in systemic lupus erythematosus susceptibility. Ann 
Rheum Dis 2007, 66:560-1. 
[123] Napirei M, Wulf S, Mannherz HG. Chromatin breakdown during necrosis by serum 
Dnase1 and the plasminogen system. Arthritis Rheum 2004, 50:1873-83. 
[124] Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD, Jr., et al. 
Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010, 
107:15880-5. 
[125] Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, et al. 
Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. 
Proc Natl Acad Sci U S A 2007, 104:6388-93. 
[126] Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I 
reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A 1990, 87:9188-
92. 
 
Experimental Sepsis Models 67 
[127] Semeraro F, Ammollo CT, Morrissey JH, Dale GL, Friese P, Esmon NL, et al. 
Extracellular histones promote thrombin generation through platelet-dependent 
mechanisms: involvement of platelet TLR2 and TLR4. Blood 2011, 118:1952-61. 
[128] Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ 
dysfunction. Thromb Res 2012, 129:290-5. 
[129] Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, et al. Extracellular 
histones are major mediators of death in sepsis. Nat Med 2009, 15:1318-21. 
[130] Marshall CJ, Nallaratnam M, Mocatta T, Smyth D, Richards M, Elliott JM, et al. Factors 
influencing local and systemic levels of plasma myeloperoxidase in ST-segment 
elevation acute myocardial infarction. Am J Cardiol 2010, 106:316-22. 
[131] Baldus S, Eiserich JP, Mani A, Castro L, Figueroa M, Chumley P, et al. Endothelial 
transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets 
of tyrosine nitration. J Clin Invest 2001, 108:1759-70. 
[132] Keshari RS, Jyoti A, Kumar S, Dubey M, Verma A, Srinag BS, et al. Neutrophil 
extracellular traps contain mitochondrial as well as nuclear DNA and exhibit 
inflammatory potential. Cytometry A 2012, 81:238-47. 
[133] Wartha F, Beiter K, Normark S, Henriques-Normark B. Neutrophil extracellular traps: 
casting the NET over pathogenesis. Curr Opin Microbiol 2007, 10:52-6. 
[134] Esmon CT. Extracellular histones zap platelets. Blood 2011, 118:3456-7. 
[135] Xu J, Zhang X, Monestier M, Esmon NL, Esmon CT. Extracellular histones are 
mediators of death through TLR2 and TLR4 in mouse fatal liver injury. J Immunol 2011, 
187:2626-31. 
[136] Lorente JA, Marshall JC. Neutralization of tumor necrosis factor in preclinical models 
of sepsis. Shock 2005, 24 Suppl 1:107-19. 
[137] Hinshaw LB, Tekamp-Olson P, Chang AC, Lee PA, Taylor FB, Jr., Murray CK, et al. 
Survival of primates in LD100 septic shock following therapy with antibody to tumor 
necrosis factor (TNF alpha). Circ Shock 1990, 30:279-92. 
[138] Lay AJ, Donahue D, Tsai MJ, Castellino FJ. Acute inflammation is exacerbated in mice 
genetically predisposed to a severe protein C deficiency. Blood 2007, 109:1984-91. 
[139] Maderazo EG, Breaux S, Woronick CL, Krause PJ. Efficacy, toxicity, and 
pharmacokinetics of pentoxifylline and its analogs in experimental Staphylococcus 
aureus infections. Antimicrobial Agents and Chemotherapy 1990, 34:1100-6. 
[140] Teti G, Mancuso G, Cusumano V, Blandino G, Fera MT, Carbone M. Effects of anti-
cytokine treatments in neonatal sepsis models. J Chemother 1995, 7 Suppl 4:96-8. 
[141] Mancuso G, Cusumano V, Cook JA, Smith E, Squadrito F, Blandino G, et al. Efficacy of 
tumor necrosis factor +¦ and eicosanoid inhibitors in experimental models of neonatal 
sepsis. FEMS Immunology & Medical Microbiology 1994, 9:49-54. 
[142] Freudenberg MA, Galanos C. Tumor necrosis factor alpha mediates lethal activity of 
killed gram-negative and gram-positive bacteria in D-galactosamine-treated mice. Infect 
Immun 1991, 59:2110-5. 
 Sepsis – An Ongoing and Significant Challenge 68 
[143] Papasian CJ, Silverstein R, Gao JJ, Bamberger DM, Morrison DC. Anomalous Role of 
Tumor Necrosis Factor Alpha in Experimental Enterococcal Infection. Infection and 
Immunity 2002, 70:6628-37. 
[144] Hinshaw LB, Emerson TE, Jr., Taylor FB, Jr., Chang AC, Duerr M, Peer GT, et al. 
Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-
TNF antibody. J Trauma 1992, 33:568-73. 
[145] Stevens DL, Bryant AE, Hackett SP, Chang A, Peer G, Kosanke S, et al. Group A 
Streptococcal Bacteremia: The Role of Tumor Necrosis Factor in Shock and Organ 
Failure. Journal of Infectious Diseases 1996, 173:619-26. 
[146] Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor 
necrosis factor protects mice from lethal effect of endotoxin. Science 1985, 229:869-71. 
[147] Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. Anti-
cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. 
Nature 1987, 330:662-4. 
[148] Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG. Anti-tumor 
necrosis factor antibody therapy fails to prevent lethality after cecal ligation and 
puncture or endotoxemia. J Immunol 1992, 148:2724-30. 
[149] Echtenacher B, Hultner L, Mannel DN. Cellular and molecular mechanisms of TNF 
protection in septic peritonitis. J Inflamm 1995, 47:85-9. 
[150] Cohen J. Adjunctive therapy in sepsis: a critical analysis of the clinical trial 
programme. Br Med Bull 1990, 55:212-25. 
[151] Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of 
Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein. N Engl J Med 
1996, 334:1697-702. 
[152] Martin GS, Mannino DM, Eaton S, Moss M. The Epidemiology of Sepsis in the United 
States from 1979 through 2000. N Engl J Med 2003, 348:1546-54. 
[153] Turnbull IR, Buchman TG, Javadi P, Woolsey CA, Hotchkiss RS, Karl IE, et al. Age 
disproportionately increases sepsis-induced apoptosis in the spleen and gut epithelium. 
Shock 2004, 22:364-8. 
[154] Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. 
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis. N 
Engl J Med 2001, 344:699-709. 
[155] Wichmann MW, Inthorn D, Andress HJ, Schildberg FW. Incidence and mortality of 
severe sepsis in surgical intensive care patients: the influence of patient gender on 
disease process and outcome. Intensive Care Med 2000, 26:167-72. 
[156] Hrekova SP, Vodianyk MO, Chernyshov VP. [Effect of progesterone and 17beta-
estradiol on proinflammatory cytokine costimulatory proliferative activity]. Fiziol Zh 
2002, 48:63-9. 
[157] England JM, Bain BJ. Total and differential leucocyte count. Br J Haematol 1976, 33:1-7. 
 
Experimental Sepsis Models 69 
[158] Northern AL, Rutter SM, Peterson CM. Cyclic changes in the concentrations of 
peripheral blood immune cells during the normal menstrual cycle. Proc Soc Exp Biol 
Med 1994, 207:81-8. 
[159] Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early Goal-
Directed Therapy in the Treatment of Severe Sepsis and Septic Shock. N Engl J Med 
2001, 345:1368-77. 
[160] Natanson C, Danner RL, Reilly JM, Doerfler ML, Hoffman WD, Akin GL, et al. 
Antibiotics versus cardiovascular support in a canine model of human septic shock. 
American Journal of Physiology - Heart and Circulatory Physiology 1990, 259:H1440-
H1447. 
[161] Ondiveeran HK, Fox- Robichaud AE. Pentastarch in a Balanced Solution Reduces 
Hepatic Leukocyte Recruitment in Early Sepsis. Microcirculation 2004, 11:679-87. 
[162] Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for 
reporting parallel group randomised trials. Int J Surg 2011, 9:672-7. 
[163] Moher D, Schulz KF, Altman DG. The CONSORT statement: revised 
recommendations for improving the quality of reports of parallel-group randomized 
trials. Ann Intern Med 2001, 134:657-62. 
[164] Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality 
of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996, 
276:637-9. 
[165] Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience 
research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 
2010, 8:e1000412. 
[166] Bebarta V, Luyten D, Heard K. Emergency medicine animal research: does use of 
randomization and blinding affect the results? Acad Emerg Med 2003, 10:684-7. 
[167] Piper RD, Cook DJ, Bone RC, Sibbald WJ. Introducing Critical Appraisal to studies of 
animal models investigating novel therapies in sepsis. Crit Care Med 1996, 24:2059-70. 
[168] Lamontagne F, Briel M, Duffett M, Fox-Robichaud A, Cook DJ, Guyatt G, et al. 
Systematic review of reviews including animal studies addressing therapeutic 
interventions for sepsis. Crit Care Med 2010, 38:2401-8. 
[169] Kilkenny C, Parsons N, Kadyszewski E, Festing MF, Cuthill IC, Fry D, et al. Survey of 
the quality of experimental design, statistical analysis and reporting of research using 
animals. PLoS One 2009, 4:e7824. 
[170] Chalmers TC, Celano P, Sacks HS, Smith H, Jr. Bias in treatment assignment in 
controlled clinical trials. N Engl J Med 1983, 309:1358-61. 
[171] Sacks H, Chalmers TC, Smith H, Jr. Randomized versus historical controls for clinical 
trials. Am J Med 1982, 72:233-40. 
[172] Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in 
comparisons of therapy. I: Medical. Stat Med 1989, 8:441-54. 
 Sepsis – An Ongoing and Significant Challenge 70 
[173] Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to 
use an article about therapy or prevention. A. Are the results of the study valid? 
Evidence-Based Medicine Working Group. JAMA 1993, 270:2598-601. 
[174] Marshall JC, Creery D. Pre-clinical models of sepsis. Sepsis 1998, 2:187-97. 
[175] Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to 
use an article about therapy or prevention. B. What were the results and will they help 
me in caring for my patients? Evidence-Based Medicine Working Group. JAMA 1994 , 
271:59-63. 
[176] Contopoulos-Ioannidis DG, Ntzani E, Ioannidis JP. Translation of highly promising 
basic science research into clinical applications. Am J Med 2003 , 114:477-84. 
